SWOG clinical trial number
SWOG-8312

Megestrol Acetate and Aminoglutethimide/ Hydrocortisone In Sequence or in Combination as Second-Line Endocrine Therapy of Estrogen Receptor Positive Metastatic Breast Cancer

Closed
Phase
Accrual
96%
Published
Abbreviated Title
Megestrol Acetate and Aminoglutethimide/ Hydrocortisone In Sequence or in Combination as Second-Line Endocrine Therapy of Estrogen Receptor Positive Metastatic Breast Cancer
Activated
05/04/1984
Closed
11/15/1990

Research committees

Breast Cancer

Publication Information Expand/Collapse

2000

Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint

R Mick;JJ Crowley;RJ Carroll Controlled Clinical Trials 21:343-359

1997

Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor positive metastatic breast cancer: A Southwest Oncology Group phase III trial.

CA Russell;SJ Green;J O'Sullivan;HE Hynes;GT Budd;JE Congdon;S Martino;CK Osborne Journal of Clinical Oncology 15(7):2494-2501

1991

Megesterol acetate (MA) and aminoglutethimide/hydrocortisone (AG) in sequence or in combination as second-line endocrine therapy of estrogen receptor positive metastatic breast cancer: A Southwest Oncology Group study.

J Congdon;S Green;J O'Sullivan;HE Hynes;R Belt;K Gail;B Zidar;CK Osborne ASCO 10:43(#45)

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
4%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase